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BACKGROUND: The metabolome of any given biological
system contains a diverse range of low molecular weight
molecules (metabolites), whose abundances can be af-
fected by the timing and method of sample collection,
storage, and handling. Thus, it is necessary to consider
the requirements for preanalytical processes and bio-
banking in metabolomics research. Poor practice can cre-
ate bias and have deleterious effects on the robustness and
reproducibility of acquired data.
CONTENT: This review presents both current practice and
latest evidence on preanalytical processes and biobanking
of samples intended for metabolomics measurement of
common biofluids and tissues. It highlights areas requir-
ing more validation and research and provides some
evidence-based guidelines on best practices.
SUMMARY: Although many researchers and biobanking
personnel are familiar with the necessity of standardizing
sample collection procedures at the axiomatic level (e.g.,
fasting status, time of day, “time to freezer,” sample vol-
ume), other less obvious factors can also negatively affect
the validity of a study, such as vial size, material and
batch, centrifuge speeds, storage temperature, time and
conditions, and even environmental changes in the col-
lection room. Any biobank or research study should es-
tablish and follow a well-defined and validated protocol
for the collection of samples for metabolomics research.
This protocol should be fully documented in any result-
ing study and should involve all stakeholders in its design.
The use of samples that have been collected using stan-
dardized and validated protocols is a prerequisite to en-
able robust biological interpretation unhindered by un-
necessary preanalytical factors that may complicate data
analysis and interpretation.
© 2018 American Association for Clinical Chemistry
The preanalytical steps in specimen acquisition and pro-
cessing are among the most crucial for producing reliable
analytical results and are highly vulnerable to the intro-
duction of experimental bias and variance. Such steps
must be conducted rigorously to preserve the intrinsic
value of the resulting specimen repository or biobank.
Biobanks are facilities where carefully collected and cu-
rated biological samples are stored and distributed for
research purposes according to approved protocols. The
samples themselves are linked to metadata, such as age,
sex, ethnicity, health status, and potentially medical re-
cords of the sample donor.
The number of biobanks around the world has in-
creased (1 ), reflecting the growing awareness of the need
for epidemiological scaled “omics” analyses. This growth
has been organic rather than structured, leading to several
differing sample collection and processing protocols. In-
creasingly, there have been attempts (e.g., International
Agency for Research on Cancer biobank, Promoting
Harmonization of Epidemiological Biobanks in Europe,
Biobanking and Biomolecular Resources Research Infra-
structure) (2–4) to harmonize and rationalize multicen-
tric sample collection and storage protocols. This reduces
interbiobank variability, thus improving comparability
of observations seen between multicenter projects.
1 Berlin Institute of Health, Berlin, Germany; 2 Max Delbru¨ck Center for Molecular Medi-
cine, Berlin-Buch, Germany; 3 UCD School of Agriculture and Food Science, Institute of
Food and Health, UCD, Dublin, Ireland; 4 School of Science, Edith Cowan University,
Perth, Australia; 5 NIH West Coast Metabolomics Center, UC Davis, Davis, CA; 6 Depart-
ment of Biochemistry and Molecular Biomedicine and IBUB, Universitat de Barcelona,
Barcelona and Centro de Investigacio´n Biome´dica en Red en Enfermedades Hepa´ticas y
Digestivas (CIBER-EHD), Madrid, Spain; 7 School of Biosciences and Phenome Centre
Birmingham, University of Birmingham, Birmingham, UK; 8 Advanced Pattern Analysis
and Countermeasures Group, Research Innovation Center, Colorado State University,
Fort Collins, CO; 9 Sovaris Aerospace, LLC, Boulder, CO; 10 Metabolomics Unit, Institute
for Molecular Medicine FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
* Address correspondence to: V.V. at Metabolomics Unit, Institute for Molecular Medicine
FIMM, University of Helsinki, HiLIFE, P.O. Box 20, Helsinki 00014, Finland. E-mail
vidya.velagapudi@helsinki.ﬁ; J.K. at BIH Metabolomics Platform, Max Delbru¨ck Center
for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany. E-mail
jennifer.kirwan@mdc-berlin.de.
Received January 31, 2018; accepted May 1, 2018.
Previously published online at DOI: 10.1373/clinchem.2018.287045
© 2018 American Association for Clinical Chemistry
Clinical Chemistry 64:8
1158–1182 (2018)
Review
1158
Most existing biobanks were established for epide-
miological purposes with either genomics or more tradi-
tional scientific analyses in mind; however, the collection
requirements for DNA extraction and analyses are fun-
damentally different than those of metabolomics because
DNA extraction is comparatively more robust (e.g., it is
still possible to achieve high yields of representative good-
quality DNA from blood even after 24-h storage at room
temperature) (5 ). By comparison, metabolism can con-
tinue in tissues or biofluids even after collection. For
subsequent measurements to bemeaningful, the metabo-
lome at the time of extraction and analysis should reflect
as closely as possible the original in vivo metabolome.
During the sample collection, the concentrations of me-
tabolites may change because of ongoing enzymatic ac-
tivities, exposure to oxygen, UV light, or temperature
(6–8 ). Protocols must reduce such effects to a minimum
and, when unavoidable, standardize exposure of samples
to such factors. Importantly, protocols should provide
evidence of experimental validation, especially robust-
ness and reproducibility of data for all protocols designed
to collect and store metabolomics samples. Fully vali-
dated protocols (8, 9 ) enhance confidence among re-
searchers and promote a gradual rationalization of pro-
tocols toward “best practice.” We define a validated
collection protocol as one where all steps have been tested
for reproducibility and robustness specifically on the
sample types being collected, with an effort to optimize
these steps, including, wherever possible, well-planned
comparisons with alternative methods. There should also
be a documented awareness of the limitations of the pro-
tocol in place, especially when compromises have been
made because of practical considerations.
There are 3 key considerations for any sample col-
lection used in metabolomics research:
• Samples should be collected in a reproducible manner
within and between different collection sites using the
same detailed protocols and the same consumables (in-
cluding brand and preferably batch number).
• Collected and stored samples should represent the in
vivo situation as closely as possible.
• The practicalities of sample collection should be con-
sidered in protocol design so that sufficient numbers of
samples can be collected with ease.
A schematic of the various stages of the biobanking pro-
cess is shown in Fig. 1.
Variables that have been shown to affect the mea-
suredmetabolome in a variety of tissue and biofluid types
include age, sex, weight, whether breast-fed (infants),
diet, ethnicity, smoking history, environment, time of
day, time of year, fasting state, current medications (in-
cluding nonprescription medications and dietary supple-
ments), physical activity, occupation, and geographic lo-
cation (10–20). These details, along with a sample of
stool or information on the gut microbiome, should al-
ways be recorded when biobanking samples and, when
possible, standardized within any individual study. For
women, recording the day of her menstrual cycle (and
any chemical contraception being used) should be rou-
tine because it may affect the metabolome of some bio-
fluids (e.g., as observed in plasma) (10 ).
Samples should be stored as multiple representative
aliquots, when possible, becausemultiple freeze–thaw cy-
cles may be detrimental to individual metabolites (21 ).
To be considered representative, an aliquot must be
taken from a freshly mixed sample because of the ten-
dency of biofluids to settle quickly. Consideration should
be given to the size of the aliquot and the size and type of
vial it will be stored in, as a large dead space volume can
affect sublimation of CO2 in long-term storage (9 ) and
certain vial materials are known to contaminate samples
(22 ).
A design consideration for sample collection that is
often overlooked but is of vital importance is the decision
as to whether targeted or untargeted analysis is to be
performed. Untargeted analysis would generally seek the
greatest molecular feature diversity and the features most
reflective of the specimen. Sample collection and process-
ing would be devised accordingly. Targeted analyses may
be willing to sacrifice breadth and diversity of molecular
features in favor of preselected analytes of interest and
optimize the processing and analytical methods best
suited for their measurement. A variation on this would
be the use of targeted analysis to capture analytes of in-
terest, while simultaneously examining the untargeted
metabolome to provide context (23 ). In such cases, sam-
ple acquisition and processing methods that optimize for
both needs may be warranted.
In this review, we examine current practice in bio-
banking samples for metabolomics and the evidence base
behind the choices that have been made in defining the
protocols, and make recommendations as to the need for
further research. A collection of protocols in use for dif-
ferent tissue and biofluid types is summarized in Tables
1, 2, and 3.
Statistical Considerations
It is important to emphasize the importance of validated
biobanking protocols with respect to the concept of ro-
bust and reproducible scientific discovery, and the statis-
tical inference on whether an observed effect is real, a
result of random chance, or a statistical error. Discovery
through random chance has been discussed previously
and, therefore, is not included (24 ) in this review; how-
ever, false discovery owing to statistical error is often the
result of inconsistent or biased sample collection. Incon-
sistent (imprecise) sample collection can increase biolog-
ical variance to the point that a given study is underpow-
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Fig. 1. Schematic of standard stages in planning tissue or body ﬂuid collection for a biobank or tissue repository.
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ered, resulting in a much higher probability of false-
negative findings (type II error). Similarly, systematic
differences in sample collection (e.g., disease samples col-
lected using a different protocol than for control samples)
result in biased statistical analysis, often with 100% con-
founding factors, which increases the probability of both
false-positive and false-negative results (type I and II er-
ror). These issues have been discussed at great length
previously (25 ), but it is important to note that com-
pounding multiple errors, because of collection variance
at multiple stages of the complete work flow, will rapidly
inflate the probability of false discovery. As such, detailed
consideration should be given to validating and optimiz-
ing each step of the work flow and ensuring consistent
collection and processing of samples through standard
operating procedures and staff training.
Preanalytical Processing and Biobanking of
Serum, Plasma, and Dried Blood Spots
Blood-based biofluids and urine are the most frequently
collected human samples in metabolomic and epidemio-
logical studies. These biofluids provide a “global” view of
metabolism operating in multiple different tissues and
organs and are relatively easy to collect. No single best
practice protocol is currently established, and samples are
typically collected according to standard blood collection
protocols (Table 1). However, as discussed below, there
are several considerations when assessing the applicability
of blood collection and processing for samples already
collected or for samples to be collected in the future.
Consistency is important whichever collection strategy is
used.
Large biobank repositories containing blood prod-
ucts (serum and plasma) are available for researchers to
access samples (e.g., the UK Biobank contains serum and
plasma samples for 500000 individuals) (26 ). Trained
phlebotomists normally collect blood, although the alter-
native option of dried blood spot (DBS)11 collection is
available. DBS offers an opportunity for collection in
environments away from the clinic, without the presence
of trained staff and without the time-related requirement
of sample centrifugation and processing. A lancet is used
to provide a finger prick to produce a small volume of
blood (up to 25L typically), which is physically spotted
onto filter paper-based collection cards (e.g., GEHealth-
care’s Whatman 903 cards) (27 ) and then allowed to dry
before storage (28, 29 ). This option allows for collection
of samples across a time series by the subject, and samples
can be sent via postal services for storage in clinical bio-
banks (e.g., a targeted vitamin D assay is operated in this
way) (30 ). Most applications focus on a targeted set of
metabolites including amino acids and acylcarnitines for
inborn errors of metabolism testing (31, 32 ) or drugs
and their metabolites in drug metabolism and pharma-
cokinetic studies (33 ). The hematocrit in the blood spot
and sample stability (34, 35 ) are important factors to
consider. Although the use of DBS for untargeted
metabolomics applications is not frequently used (36 ),
there is a growing interest in its potential use because
DBS offers some advantages over plasma and serum and
removes several preanalytical factors discussed below.
However, 1 major consideration is the stability of DBS at
different drying times, drying and storage temperatures,
and storage times (35, 36 ). Further investigations of the
stability of different metabolite classes or individual key
metabolites are required before epidemiological studies
using DBS can be performed.
Collection of Blood Products
Plasma and serum can be considered as 2 different bio-
fluids both originating from blood. Plasma is collected
using anticoagulants and, thus, preserves most clotting
factors, whereas serum is produced using a natural blood
clotting process. The question of whether serum or
plasma should be collected is important because the pro-
duction of serum involves coagulation, whereas plasma
does not. The time and temperature allowed for coagu-
lation are important preanalytical factors to consider and
should be standardized for sample processing. Special
care should be taken during drawing and handling of
samples to avoid hemolysis. The release of hemoglobin
and other intracellular components from erythrocytes
can markedly alter plasma/serum metabolomic profiles
(37, 38 ); thus, hemolyzed blood samples should be
avoided in metabolomics studies. Studies comparing se-
rum and plasma from the same individuals have de-
scribed only small qualitative and quantitative differences
for the metabolite composition of the 2 biofluids, and
this variability is less when comparing with the biological
variability observed between different persons (39–41).
For example, higher concentrations of some metabolites
have been reported for serum compared with plasma col-
lected from the same individuals; in 1 study, 9 metabo-
lites were reported to have20% greater concentrations
in serum than in plasma including amino acids (glycine,
serine, phenylalanine, and arginine), lysoglycerophos-
pholipids (C16:0, C17:0, C18:0, and C18:1), and glyc-
erophosphatdylcholines (C38:1) (39 ). Therefore, there
is no clear conclusion on which biofluid to collect, al-
though the same biofluid should be used in any single
study. Plasmamay have some advantages over serum, as a
more standardized collection and extraction procedure
11 Nonstandard abbreviations: DBS, dried blood spot; NMR, nuclearmagnetic resonance;
FOBT, fecal occult blood test; FIT, fecal immunochemical test; CSF, cerebrospinal ﬂuid.
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can be used without concern regarding how the clotting
procedure may influence the metabolome (42 ).
The collection of blood and its processing should be
performed according to standard protocols (Table 1).
Preanalytical factors are important for blood, which is
metabolically active, primarily through cellular metabo-
lism (especially erythrocytes), to ensure that the postpro-
cessed sample is a qualitative and quantitative represen-
tation of the sample at the time of collection (43 ).
Time of Sample Collection
The time of day a blood sample is collected can influence
the quantitative composition of serum and plasma sam-
ples as shown by several diurnal studies (11, 44, 45 ). The
time of day and season were not significant sources of
variation in 1 study, but it is recognized that this finding
is not conclusive for all studies, and a standardized col-
lection within the same time of day and in either fasted or
fed status is recommended (46 ).
Type of Plasma Collection Tube
Three standard types of anticoagulants can be applied for
collection of plasma samples: lithium (or sodium) hepa-
rin, sodium citrate, and potassium ethylenediaminetet-
raacetic acid (EDTA) (30 ). Citrate and EDTA are low
molecular weight chemicals and can interfere in the de-
tection of metabolites in untargeted metabolomics stud-
ies and will also be detected by most analytical platforms.
In addition, 2 further disadvantages of citrate include
that it is an endogenous metabolite and that it can alter
the pH of the sample and, therefore, the extraction con-
ditions (47 ). Heparin is not detected in a typical untar-
geted metabolomics assay, which is advantageous, al-
though the introduction of lithium into the sample can
result in unwanted lithium adducts inmass spectrometric
analyses. EDTA-based samples are also used frequently
and may be more advantageous if concurrent proteomics
is planned with the same sample.
Type of Serum Collection Tube
There are 2 types of serum collection tubes: gel-free and
gel-containing (polymeric) tubes (48 ). The quality of
these tubes is important, and the use of gel-free tubes
removes the possibility of sample contamination from
the gel (polymer). Lopez et al. assessed polymeric and
nonpolymeric tubes for serum and EDTA plasma pro-
cessing and showed no differences in the metabolic pro-
file for plasma EDTA tubes but did show differences
between polymeric and nonpolymeric tubes for serum,
although no preferred tube was indicated (49 ).
Inversion of Plasma Tubes
Tubes are inverted gently several times to allowmixing of
anticoagulants with whole blood, and a lack of standard-
ization of this process can be expected to influence the
qualitative and quantitative composition of the processed
plasma sample.
Processing Location, Temperature, and Time
Intervals
Whole blood can be processed at the site of sample col-
lection or at a central processing facility (50, 51 ). Studies
have investigated whether transport to a central process-
ing facility can be undertaken rather than rapid process-
ing and concluded that, if samples were stored cold
(4 °C), delayed processing had only minor influences on
the metabolic profile, and the differences observed re-
lated to processing were much smaller than intersubject
differences (21, 52 ). Processing should be undertaken
before freezing the samples because freezing whole eryth-
rocytes will result in their lysis and substantial contami-
nation of the plasma metabolome.
The associated temperature for storage and the time
between whole blood collection and centrifugation are
important preanalytical factors. Whole blood stored at
room temperature is much more metabolically active
than that stored on ice at approximately 4 °C, which will
greatly affect the quantitative metabolic profile. We rec-
ommend a short processing time (30 min) if storage is
at room temperature, but storage at 4 °C on ice or in a
refrigerator for longer periods is accepted by some large
biobanks. Again, the variability introduced by different
storage times and temperatures is low compared with the
biological variability observed when studying the human
population (8, 21, 52–56). Two separate studies have
recommended processing within 3 h at 4 °C whenever
feasible (8, 53 ). Jain et al. (55 ) have demonstrated met-
abolic changes measured up to 20 h before centrifuga-
tion, with metabolites related to erythrocyte metabolism
showing the greatest change, and with lactate and argi-
nine/ornithine being potential markers of instability. Tr-
ezzi et al. (8 ) have established a novel blood sample qual-
ity control marker, the LacaScore, based on the ascorbic
acid/lactate ratio in plasma.
Centrifugation time and temperature must be
consistent according to a standard operating proce-
dure (Table 1). Some metabolites are unstable even
under acceptable processing conditions, including cys-
teine and cystine (54 ).
Long-Term Storage Temperature
Until recently, plasma and serum were considered meta-
bolically inactive after separation from cells in whole
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blood. Quantitative changes in some metabolites can oc-
cur even in samples stored at 80 °C, often displaying
nonlinear patterns of concentration change (57 ). There-
fore, we recommend that samples always be stored fro-
zen, preferably in liquid nitrogen or at 80 °C when
liquid nitrogen is not available and analyzed within the
shortest time window possible after collection. We rec-
ommend storing samples from an individual in multiple
0.5- or 1.0-mL aliquots. This minimizes any need for
multiple, potentially damaging, freeze–thaw cycles should
an individual’s sample require multiple analyses (56). The
number of temperature change cycles, e.g., because of the
freezer door being open, is also likely to be important for all
tissue types, although thus far little investigation has been
done on this phenomenon (58).
Sample Stability
Although inappropriate thawing of samples and multiple
freeze–thaw cycles are likely not appropriate, limited re-
search has been reported to assess this process. Pizzaro
et al. have reported that the thawing temperature was
important and recommended thawing small aliquots
(0.25 mL) on ice for lipids and that ultrasound thawing
improved sensitivity and detection for lipid studies (59 ).
Breier et al. showed that 2 freeze–thaw cycles did not
influence the metabolic profiles in a targeted assay (21 ),
but when possible, individual laboratories should con-
duct their own freeze–thaw investigations on metabolites
of interest. Where freeze–thawing cannot be avoided, the
number of freeze–thaw cycles should be recorded and
standardized among samples in the same study to avoid
bias and enable it to be included as a confounding factor
when analyzing the data.
RECOMMENDATIONS
Blood products are probably the best studied and vali-
dated biofluids for metabolomics. Therefore, we recom-
mend that the selection of an appropriate protocol is
based on access to validation data demonstrating the ro-
bustness of the protocol.
Preanalytical Processing and Biobanking
of Tissues
A detailed metabolic phenotypic analysis of tissues re-
flects their physiological and pathological status (60 ).
However, obtaining systematic and reproducible results
in tissue samples is challenging because of the complex
nature of the samples and diversity of the metabolites.
Thus, establishing work flow pipelines and standardized
protocols for tissue metabolomics is of utmost importance,
especially focusing on the preanalytical steps, which can in-
troduce huge variability in the subsequent analyses (61–
64).The evidencebase for different tissue types is variable.A
summary of protocols for tissues with medium to well-
defined evidence-based protocols is outlined in Table 1,
whereas tissues for which substantially more validation re-
search is needed are featured in Table 2.
Collection of Tissues
Want et al. (65 ) recommended that the timing of the
tissue sample collection for controls and cases be ran-
domized.When compared with collection of biofluids or
blood, which can be collected easily and noninvasively,
additional care should be taken for tissue samples. Tis-
sues are normally collected with anesthesia or at autopsy,
which may pose several problems. To obtain reliable me-
tabolite profiles, sampling should occur as quickly as pos-
sible, which can create challenges in an operating theater
(43 ). To measure extremely labile metabolites as accu-
rately as possible, subsequent immediate flash-freezing
on collection is required to avoid further metabolism in
the samples (66 ). However, in an operating theater, there
may be safety issues with having liquid nitrogen present.
By contrast, placing a warm tissue directly into a80 °C
freezer may enable the metabolic profile to change in the
time it takes for the sample to freeze and, thus, is not
optimum. To avoid contamination, as much blood as
possible should be removed from the tissue samples (67 ).
Because most tissues are heterogeneous, for repeatable
results the location of the tissue sampling should be con-
sistent throughout the same experiment to avoid region-
specific metabolite variance if there is a limitation in ob-
taining the whole tissue for metabolomics analyses (65 ).
Usually needle (e.g., organs) (68, 69 ) or punch (e.g.,
skin) (70 ) biopsies are carried out to collect the human
tissues for metabolomics analyses, and care should be
taken to avoid unnecessary biopsy-associated complica-
tions in the patients (71 ).
Important spatial information can be obtained from
tissue sample metabolite analyses. Latest state-of-the-art
technologies like mass spectrometry-based imaging anal-
ysis using, for example, MALDI-TOF MS, facilitates
“spatial metabolomics” (72, 73 ). For tumor sample anal-
ysis, additional care should be taken about the location
of sample collection (e.g., oxygenated vs necrotic areas)
(65 ) and collection of “normal” tissue as a control
(74, 75 ). Hence, careful and detailed experimental de-
sign is required considering what is the best representa-
tive tissue sample in terms of location, sample amount,
and the required number of biological replicates for bet-
ter statistical power in data analyses.
Storage of Tissues
As for blood, tissue samples should be stored at 80 °C
or lower for long-term storage for future metabolomics
analyses. Sectioning large tissue samples into smaller
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pieces may facilitate quick freezing and avoid future
freeze–thaw cycles, although consideration should be
given to the likely metabolite changes that may occur
dependent on the sectioning technique and resulting
time delay. However, considering that tissues are hetero-
geneous samples (e.g., metabolomic alterations during
acute kidney injury are different in kidney cortex and
kidney medulla), another possibility is using a tissue ho-
mogenizer or a clean uncontaminated mortar and pestle
with liquid nitrogen and subaliquoting by weight to ob-
tain homogeneous and representative samples (76–78).
Unlike other sample types, there may be other require-
ments for their use, such as histology, which may influ-
ence which protocols can be used for processing for stor-
age. There are usually only limited amounts of tissue
samples available, especially in the case of human biop-
sies. Thus, care should be taken while collecting for sub-
sequent aliquoting and storing at appropriate conditions,
with consideration given to avoid contamination when
slicing or homogenizing.
RECOMMENDATIONS
We recommend that tissue-specific sampling protocols
be used. In general, tissue samples should be collected as
quickly as possible, flash frozen in liquid nitrogen, and
stored at80 °C or lower for long-term storage. Freeze–
thaw cycles should beminimized asmuch as possible, and
subaliquoting the tissue samples while collecting will re-
duce the future freeze–thaw cycles. For repeatable results,
the location of the tissue sampling should be consistent
throughout the same experiment to avoid region-specific
variance.
Preanalytical Processing and Biobanking
of Urine
In recent years, metabolomic studies using urine have
clearly demonstrated its usefulness in a range of disciplines.
Furthermore, urine is easy to collect and is abundant with
metabolites that reflect food intake, environmental expo-
sures, and alterations in biochemical pathways.However, to
ensure that the results obtained are meaningful, it is imper-
ative that attention is given to sample collection conditions,
storage conditions, and postcollection treatment. A sum-
mary of protocols can be found in Table 1.
Collection of Urine
Urine samples can be collected as either a single mid-
stream collection at a specific time (spot urine samples) or
the total urine output in a period of 24 h (24-h samples).
In both cases, it is important to prevent bacterial growth
and ensure stability of the metabolites. It is now accepted
that collected human urine is not sterile because of con-
tamination by bacteria in the urethra (79 ). Indeed, bac-
terial growth in collected urine can be rapid and can
modify metabolite composition. A recent study designed
to examine the impact of sample collection conditions on
the metabolite composition demonstrated that addition
of preservative prevented bacterial growth but did not
avoid metabolite degradation (80 ), whereas storage at
4 °C inhibited bacterial growth and metabolite degrada-
tion. This has important consequences for collection of
24-h urine samples; to preserve the integrity of the sam-
ple, the results from this study support maintaining sam-
ples at 4 °C during the collection period.
Depending on the research question, either spot
urine or 24-h urine samples can be collected. A research
question may be more suited to the use of one over the
other. Participants’ state of fasting is important for spot
urine collection. Food intake has a substantial impact on
the urinary metabolic profile (13 ), which should be con-
sidered in the design of collection protocols.
An advantage of using urine is the possibility of
home sampling, which facilitates interventional study de-
signs. However, special care must be taken regarding the
use of inadequate urine collection containers and im-
proper conditions of storage and transportation to repos-
itories (81 ).
Processing Location, Temperature, and Time
Intervals
A recent study by Rotter et al. (82 ) used a targeted ap-
proach to measure the stability of 63 metabolites under
different storage conditions in the short term—a period
that reflects the sample collection period. More specifi-
cally, the study investigated storage at80 °C,20 °C,
4 °C, 9 °C (cool pack), and room temperature for 0, 2, 8,
and 24 h. Interestingly, about 90% of the targeted me-
tabolites were not significantly altered by any of the con-
ditions when compared with the samples immediately
frozen at80 °C. However, storage in a cool pack and at
room temperature resulted in changes in certain metab-
olites. Therefore, their recommendationwas not to trans-
port or store samples for8 h in a cool pack or at room
temperature. By contrast, the Da Vinci biobank recom-
mends storing urine for nuclear magnetic resonance
(NMR) for no more than 2 h at 4 °C and centrifuging
before freezing to avoid cell lysis (83 ).
Processing of collected urine is equally important.
Bernini et al. (84 ) examined this step and concluded that
a mild centrifugation and filtration step is necessary to
ensure removal of cellular components. Care is required
with filtration because there is the potential for loss of
metabolites. As a result, many studies process urine sam-
ples using centrifugation only. Typical centrifugation
conditions include centrifugation at 2000g for 10 min
(see Table 1).
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Storage of Urine
Once collected, a decision on the long-term storage con-
ditions for the samples is necessary. Leparre et al. recently
examined the long-term storage of urine samples using
both targeted LC-MS metabolomics and a global profil-
ing approach and found that storage at20 °C for short
periods (up to 20 days) was sufficient but that storage at
80 °C was recommended for longer periods to ensure
the stability of sensitive metabolites (85 ). This is also
supported by previous literature predominantly per-
formed using NMR as the analytical technique. Earlier
studies using NMR demonstrated that at storage condi-
tions below 20 °C for 26 weeks there was limited im-
pact onmetabolite profile (86 ). Shorter-term studies also
demonstrate stability of metabolites when stored at
80 °C and changes in metabolite profiles when storage
was performed at room temperature (80, 84, 87 ).
Sample Stability
Several studies have examined the effects of freeze–thaw
cycles on metabolite concentrations in urine samples.
Earlier studies investigating the impact of freeze–thaw
cycles focused on metabolite profiles and assessed the
statistical impact using principal component analysis.
Gika et al. examined the metabolite profile and reported
no major global changes after 9 freeze–thaw cycles (88 ).
However, using targeted analysis, Saude and Sykes re-
ported an intermediate amount of change in metabolite
concentrations after 8 freeze–thaw cycles (89 ). More re-
cently, Rotter et al. demonstrated that 2 freeze–thaw cy-
cles had no impact on metabolite concentrations (82 ).
However, after 3 cycles, significant effects were identi-
fied, leading to the recommendation to limit the number
of freeze–thaw cycles.
RECOMMENDATIONS
The overall evidence supports the following recommen-
dations: storage of urine samples chilled during collection
(4 °C if possible), centrifugation as soon as possible, and
long-term storage at 80 °C. Addition of a preservative
is not necessary if samples can be maintained at 4 °C.
When frozen, the number of freeze–thaw cycles should
be limited to 2.
Preanalytical Processing and Biobanking
of Feces
Sample acquisition, sample processing, and sources of
experimental variability in serum, plasma, and urine
metabolomics studies have been characterized in greater
depth (90–92) than in the field of fecal metabolomics.
Substantial progress has been made in nucleic acid-based
metagenomic analysis of fecal microbial composition and
diversity. The literature on sample acquisition, process-
ing, and management for fecal metabolic phenotyping is
less well developed (Table 3). Although LC-MS and
GC-MS are the most widely used analytical platforms in
metabolomics, the use of 1H NMR spectroscopy has
been the most common tool used in fecal metabolic phe-
notyping (93, 94 ). The present discussion addresses crit-
ical elements to be considered in sample acquisition, a
minimal set of recommended elements of sample acqui-
sition, and a recognition that much work is needed to
establish best practices for this specimen type.
Feces are considered a noninvasive proxy for the
study of the intestinal microbiome andmetabolome. As a
specimen, feces present several analytical challenges be-
cause solid waste is a heterogeneous complex of dietary
precursor molecules, undigested material, microbes, mi-
crobial fragments, microbial metabolites, and host cellu-
lar and molecular elements. In this context, the gut
metabolome is a representation of host metabolism, mi-
crobial metabolism, host–microbial cometabolism, and
environment (95 ). For these reasons, removal of solid
particles, dead bacteria, and undigested matter from fecal
specimens is frequently considered (96 ). This contrasts
with urine and plasma, which generally require no extrac-
tion and to which the addition of buffer solutions is
sufficient.
Collection of Feces
To adequately reflect the associated molecular diversity,
the manner of feces collection is of considerable impor-
tance. There are 2 basic specimen considerations. The
most simple and scalable method (for large studies) is to
obtain a fecal specimen by paper tissue or swab (spot
sampling). The alternative method is the use of whole
bulk feces, which can be aliquoted for specific analytical
uses. Although the fecal metabolome literature using the
swab technique is limited, the stool microbial meta-
genome literature is instructive. Several technologies exist
to extract spot samples for microbial metagenome analy-
sis. However, to date, the fecal metabolome literature
predominantly reports on bulk stool as the primary spec-
imen. A recent NMR-based fecal metabolome study ex-
amined stool homogeneity, obtaining specimens from 4
locations (e.g., top, edge, middle, and bottom) of the
bulk stool specimens. Principal component analysis re-
vealed that the crude fecal samples collected from differ-
ent positions were widely distributed in the metabolic
space, and orthogonal partial least-squares discriminant
analysis further showed that the sample composition be-
tween topographical positions and whole sample homog-
enate was significantly different (97 ). This contrasts with
microbial species composition, which has been observed
to be more homogeneous across bulk stool (97 ). From
the evidence to date, a balance must be struck between
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ease of sample collection and the heterogeneity of bulk
feces. When considering either spot or bulk sampling
method, issues of the topographical homogeneity/heter-
ogeneity of the fecal specimen should be considered.
Timing related to collection of stool is generally ran-
dom unless modifiers of stool frequency and consistency
(e.g., laxatives) are used. When such modifiers are used,
the method used and its influence on the metabolome
should be carefully noted and considered. Timing of food
intake should also be considered. Stool microbiome stud-
ies have generally been conducted, using overnight fasts,
unless specific dietary questions are being addressed in
the study. A recent study showed that a given dietary
substrate load (e.g., banana vs cookie) may evoke sub-
stantially different responses between individuals (e.g.,
serum glucose) and that these differences may, in part, be
driven by the gut microbial community structure (98 ).
Thus, dietary intake should be carefully controlled or
monitored, depending on the research question. Samples
collected with no additives are suitable for untargeted
metabolomics analysis when frozen shortly after collec-
tion, i.e., storage at 80 °C within approximately 30
min after collection (99 ). This is considered the gold
standard in fecal metabolome analysis. Recently, Loft-
field et al. collected fecal samples from 18 volunteers,
using 4 methods: no solution, 95% ethanol, fecal occult
blood test (FOBT) cards, and fecal immunochemical test
(FIT). One set of samples was frozen after collection (day
0) and for 95% ethanol, FOBT, and FIT. A second set
was frozen after 96 h at room temperature. Using untar-
geted metabolomics, stability was examined after 96 h at
room temperature for 95% ethanol, FOBT, and FIT,
along with concordance of metabolite measures with fro-
zen day 0 samples without solution (99 ).Metabolite con-
cordance with the gold standard was higher for 95%
ethanol (median rs 0.82), followed by FOBT (median
rs  0.70) and FIT (median rs  0.40).
There is a general question regarding which type of
preprocessed sample is optimum for fecal metabolome
analysis. Presently, there are 3 primary sample types be-
ing explored, which include crude fecal samples (100 ),
fecal water extracts (97, 100–103), and lyophilized feces
(103, 104). Each may yield a slightly different metabo-
lite profile. For instance, Phua et al. compared lyophi-
lized human feces vs fecal water using a GC-TOF MS
method. Lyophilized feces demonstrated a larger number
of chromatographic peaks (704 vs 664), reflecting more
comprehensive metabolic coverage. Nonpolar metabo-
lites, such as phenolics, sterols, esters, long chain alco-
hols, and long chain carboxylic acids, were higher in ly-
ophilized feces compared with fecal water. Amino acids
and carbohydrates were lower in lyophilized feces com-
pared with fecal water (105 ). Freeze-drying can provide
for greater precision in mixing of dry stool material with
solvents and derivatization agents (enhancing reproduc-
ibility). However, concerns have been raised that certain
molecular classes, such as short chain fatty acids (acetate,
propionate, and butyrate) can be adversely affected by
lyophilization. Such concerns may need to be addressed
by aliquoting samples, identifying specific molecular tar-
gets, and applying specific preservation techniques (e.g.,
HCl) for specific targetmolecules (e.g., butyrate) to those
aliquots. For instance, attention to the volatile molecular
class has been addressed by transfer of aliquots from bulk
specimens to head space vials (106 ). Additional work will
be required to determine optimumprocessing techniques
for targeted and untargeted analyses.
One means to address sample stability is centrifuga-
tion, in some cases, followed by filtration. The centrifu-
gation (and filtration) step is intended to remove cellular
components, which has the effect of substantially reduc-
ing active biochemical processes in the sample and their
attendant contribution to ongoing molecular flux within
the sample. This is a crucial step in deriving fecal water
from bulk feces. Although centrifugation and filtration
(Table 3) may prevent continuation of metabolic pro-
cesses because of cellular activity, it may also result in
reduction of molecular feature diversity.
Storage of Feces
There is a paucity of data on the long-term storage of fecal
samples for metabolomics purposes. However, examina-
tion of fecal microbiome samples used to study microbial
DNA integrity and fecal protein is informative. Kia et al.
freeze-dried human fecal samples, stored them for 14
years at20 °C, and compared the DNA integrity with
freshly collected human fecal specimens (107 ). The
DNA from the retained extracts was more sheared than
that of fresh samples, but it was still of sufficient molec-
ular weight to support amplicon-based studies. Morris et
al. (108 ) examined protein content and protease activity
on fecal samples stored for up to 1 year at 20 °C and
80 °C, and in a variety of storage buffers, and showed
that extracted protein was not stable and activity was lost,
even with a suitable storage buffer. The most robust so-
lution was to store the proteins in an intact frozen native
fecal matrix and extract at the time of assay or analysis.
This approach was shown to be appropriate for samples
that had been frozen for 1 year and that possessed low
levels of protease activity (108 ). In contrast to the above,
Gratton et al. observed notable stability differences be-
tween whole feces and fecal water, with fecal water dis-
playing the greatest stability (97 ).
Freeze–thaw cycles are generally problematic in
metabolomics studies (42 ), and examination of the fecal
metabolome is no different. According to Cardona et al.
(109 ), if frozen fecal samples are going to be transported,
it should be done as quickly as possible, preferably on ice,
to avoid a thawing event. As noted previously, the gold
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standard is to freeze samples at 80 °C within 30 min.
However, Gratton et al. have argued that if a freeze–thaw
cycle might be introduced during the transport, refriger-
ation for the first 24-h postcollection may be preferred,
followed by freezing on arrival at the sample destination
(97 ). Distribution of raw samples into aliquots before
freezing or processing is a reliable means to avoid future
freeze–thaw cycles, but an initial freeze–thaw cycle dur-
ing transport should be avoided.
Given that gastrointestinal bleeding is commonly
encountered in the clinic, there is a growing interest in
the extent to which fecal occult blood may affect the
analysis and interpretation of the fecal metabolome. Re-
cently, principal component analysis revealed that occult
blood (1 mg Hb/g feces) exerted only a minor effect on
the fecal metabolome. However, feces spiked with gross
blood (100mgHb/g feces) yielded a unique metabotype,
suggesting that attention should be given to gastrointes-
tinal bleeding in fecal metabolomics studies (105 ).
RECOMMENDATIONS
The above evidence supports attention to the following,
with a clear need for further development in this field:
bulk stool collection, when possible. Recognize that spot
sampling may introduce significant metabolite variance.
Freeze any sample collected on site within 30min of sample
collection. If transported, do not allow for a freeze–thaw
cycle. Some groups advocate that if a thaw cycle is antic-
ipated in transport, samples should be refrigerated rather
than frozen on collection. When nucleic acid-based met-
agenomic analysis and metabolite profiling are a compo-
nent of the same study, homogenization is also highly
recommended. Spot sampling from multiple locations
on the bulk stool is recommended, followed by homog-
enization. Dispense homogenized samples into multiple
aliquots to avoid freeze–thaw cycling in future analyses.
Avoid 1 freeze–thaw cycle. Short-term storage should
be optimally at80 °C andminimally at40 °C. Long-
term storage should be only at 80 °C. In the analysis,
presence of occult blood should be examined. Large-scale
studies may want to begin with pilot studies to optimize
the method to the research question, while considering
the basic principles described herein. Critical among
these considerations is whether to use crude fecal sam-
ples, fecal water extracts, or lyophilized feces, coupled
with consideration for their respective feature yields. If
spot testing cards are used, they should be from a homog-
enate specimen of 1 spot-collection site on the bulk
feces specimen. If using lyophilized specimens, collect
bulk sample, homogenize, transfer homogenate of suffi-
cient mass (e.g., 100 mg), lyophilize, and transfer to a
polypropylene tube for immediate freezing and storage at
80 °C. For fecal water extraction, 15-g sample
should be from a homogenate of1 spot-collection site
of bulk feces. Fecal methods are commonly optimized for
untargeted metabolomics, but if targeted metabolomics
is a component of the study, individual aliquots of ho-
mogenate should be prepared in a manner that optimizes
recovery of the specific analytes of interest.
Preanalytical Processing and Biobanking
of Saliva
Saliva is probably the most commonly collected “other”
fluid because it can be collected noninvasively and repeat-
edly. It has been used in studies ranging from dementia
(110, 111) to cancer (62, 112) and oral disease (113, 114).
Currently, there are saliva collection protocols in existence,
but most biobank protocols are not designed around
metabolomics research and alternative metabolomics-
specific protocols have not been well validated (Table 2).
Given the propensity for both food debris and oral bac-
teria in saliva samples to both degrade and contaminate
the in vivo metabolomics profile (110 ), protocols should
consider this risk at the time of collection and take steps
to mitigate it early after the collection period.
There are multiple published protocols for the col-
lection of saliva samples but little published validation of
the methods used. Saliva is typically collected either by
stimulation with a noxious substance, free spitting, or
chewing on a synthetic tampon followed by an extraction
procedure (typically centrifugation) to reclaim the fluid.
Stimulated collectionmethods are reported to change the
ratio of metabolites to each other (12 ), and chewing
may alter hormone concentrations (115 ), suggesting un-
stimulated passive collection as the best approach. Show-
ing pictures to increase saliva production may be benefi-
cial (115 ).
Before collection, there are various intervals of fast-
ing, tooth brushing, and smoking allowed or docu-
mented. Most are in the duration of 1 to 2 h but range
from no abstinence recorded (11 ) to 3 h (116 ). It is
unclear how much effect the length and type of any such
restrictions has on the eventual metabolome. Circadian
rhythms, smoking, periodontal disease, and fasting states
have all been reported as affecting the salivary metabo-
lome (12, 62, 113).
Both no rinsing and rinsing with water before col-
lection are strategies that are frequently used (111, 116–
119). Rinsing with water may dislodge and remove the
worst food debris in the mouth, but it may also act to
stimulate the salivary glands, thus both changing and
diluting the sample. Overall, rinsing with water is prob-
ably a sensible strategy, although it should be both con-
sistent and recorded in both the standard operating pro-
cedures and any subsequent publications.
Handling of the sample both during and after col-
lection will influence the eventual analysis results. The
time at 4 °C before freezing ranges from30 min (120 )
to1 days (110 ). Schipper et al. (121 ) and Sugimoto et
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al. (120 ) have both cited concerns that the salivary
metabolome is unstable kept at these temperatures for
long periods. It is probably preferable to freeze the saliva
after collection in a defined and recorded time window
and preferably as soon as possible after collection. Cen-
trifugation before freezing is common (111, 117, 120)
and is probably recommended because it removes food
debris and cellular material before storage (43 ). How-
ever, a systematic evaluation of the optimal time, temper-
ature, and duration for centrifuging is required.
Longer term storage should be at80 °C or below.
Storage at 20 °C has been shown to be suitable for
short-term storage for NMR in some limited studies
(12 ), but because degradation of metabolites in other
biofluids has been demonstrated to occur at these tem-
peratures (22 ), 80 °C is preferable if available.
For saliva, not enough evidence exists to recommend
one specific protocol over another. Validation of temper-
ature of collection and storage protocols, and especially
the effects of storage at 4 °C, should be investigated for
metabolomics research. Detailed collection protocols
should be drawn up and standardized for any individual
biobank and recorded in the methods when publishing
new research.
Preanalytical Processing and Biobanking of
Cerebrospinal Fluid
The collection and biobanking of cerebrospinal fluid
(CSF) has been well reviewed by Teunissen et al. (122 ),
and we support most, but not all, recommendations
made in this article. Suggested modifications to their rec-
ommendations include centrifugation (2000g for 10 min
at 4 °C) before storage to remove and prevent any cells in
the CSF lysing on thawing. This step is important even
when no obvious erythrocyte contamination is evident
(123, 124). Blood and other cells affect the protein con-
tent of the CSF, which can affect the metabolite analysis
(125, 126). Likewise, following collection, keeping the
sample at room temperature for the 2-h period may be
too long to prevent the degradation of certainmetabolites
(e.g., certain amino acids). At a minimum, the time from
collection to processing should be both recorded and
consistent between samples. Otto et al. (124) recom-
mended a maximum of 1 h at room temperature, which
appears to be a reasonable compromise. Precentrifuging
the samples and removing cellular material may lengthen
this time window (123 ).
Wuolikainen et al. (22 ) looked at storage conditions
for CSF. Sublimation of CO2 will variably affect the pH
of samples and, thus, the subsequent analysis. Therefore,
we recommend storage at80 °C or colder in the small-
est possible container with a close-fitting screw cap. Re-
garding collection and storage materials, polypropylene
tubes were first proposed for CSF collection because
some proteins stick to plastic (127 ). Polypropylene
appears to have now become standard and has been
used in a wide variety of metabolomics CSF studies
(122, 128, 129). Wuolikainen et al. (22 ) demonstrated
both how the material properties of the tubes and the
order of tube collection affected the analytical results, but
little systematic evaluation of tube material has been at-
tempted for metabolomics. In proteomics, more exten-
sive evaluation has been undertaken, which is broadly
reviewed by Willemse and Tuenissen (130 ), including
the propensity for tubes to release their own contami-
nants into the sample. Overall, when possible, sample
tubes should be bought in bulk and the same batch used
for an individual study.
Because the first 1 or 2 mL of CSF is the most likely
to be contaminated with blood, we support the recom-
mendation that it should be used for medical testing or
otherwise discarded, rather than kept for biobanking
(124). Any obvious blood-contaminated samples should
likewise be discarded.
Because the variation between the ratio of blood
concentrations of certain metabolites and the CSF con-
centrations may be indicative of certain disease states
(131–133), consideration as to whether a blood plasma
sample should be collected and analyzed alongside the
CSF sample should also be determined.
Overall, the existing protocol for CSF collection,
when followed, should be sufficient for metabolomics if
centrifugation of samples and time to freezing are both
considered and optimized. The size and material of stor-
age containers and the temperature of storage are factors
that will directly affect analysis results, and there is some
evidence that natural diurnal variation may occur in
some CSF metabolites, supporting that time of day of
collection should be standardized (134).
Preanalytical Processing and Biobanking for
Other Bioﬂuids
Other biofluids that have been used for metabolomics
include sweat (135 ), human breast milk (136 ), lacrimal
fluid (137 ), endometrial, peritoneal, follicular, and syno-
vial fluids (138–141), breath and other volatiles (142),
and microdialysates (143, 144). Collection procedures
(Table 2) for many of these fluids have not been system-
atically evaluated, especially in humans. Therefore, we
recommend that, until further validation has been con-
ducted, protocols should be adapted from existing pro-
tocols for similar metabolomics research.
Some fluid-specific issues are worth highlighting.
For breast milk, freezing is a useful way of agglutinating
micelles, and thus removing insoluble components from
the analysis (145, 146). For peritoneal fluid, endometrial
fluid, and menstrual effluent, the World Endometriosis
Research Foundation published guidelines based on best-
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practice biobanking for these biofluids (115 ). With cur-
rent knowledge, the protocols outlined in this review for
peritoneal and endometrial fluid are broadly sufficient
for most metabolomics research.
For exhaled breath condensate, the American Tho-
racic Society and the European Respiratory Society pub-
lished a list of guidelines in 2005 (147) on the collection
of this type of specimen. This was recently updated as a
technical standard for exhaled biomarkers in lung disease
(148). We recommend that the metabolomics commu-
nity follow the suggestions and good practices outlined in
this document when collecting samples for any metabo-
lome analysis involving the collection of exhaled breath
condensate. Unfortunately, these guidelines do not cover
other methods of collecting and storing volatiles.
Ethics of Sample Collection
The issue of biobanking and the wider issue of “big data”
introduce some new ethical obstacles, including:
1. New models of consent based around a “known un-
known” for both the scientist and the donor about the
full implications and uses that the samples may be
used for (149).
2. The ability of the data to stay truly anonymous, espe-
cially once coupled with other omic or metadata and
with an increasing emphasis on sharing data sets
(150 ).
3. Rights and restrictions of the individuals to access
their own data, especially when it may affect both
their own and their family’s health (151 ).
4. Rights and restrictions of others (e.g., insurance provid-
ers, employers, or healthcare companies) to potentially
use that data for commercial or alternative purposes
(152 ). The establishment of commercial biobanks
is an interesting development that raises new ques-
tions in this area.
5. The legality, ability, and ethics of biobanks and re-
searchers sharing biosamples across international bor-
ders (153 ).
Harmonizing collection procedures, ethical consent pro-
cesses, and documents between biobanks is possible and
has been demonstrated to be effective and may enable
more effective use of resources (153 ).
Conclusions
Sample collection procedures must be carefully consid-
ered when biobanking for metabolomics studies. Sub-
standard treatment of samples during the preanalytical
phase can add substantial variation or bias that may result
in misleading analytical results. Procedures that are based
on well-validated and evidence-based methodologies
should be followed whenever possible, although practi-
calities sometimes play a role in the final procedure ad-
opted, and the burden on both the volunteer donating
the samples and the staff collecting them needs to be
considered. Comprehensive staff training is a worthwhile
endeavor, so that every member of the collection and
storage team appreciates the importance of rigidly adher-
ing to the protocol, especially because consistency in im-
plementing that protocol is an important tool in contrib-
uting to reproducibility of results. Once a robust protocol
has been developed and defined, it can then be used for
future collections. Hence, it is worthwhile taking the
time and effort to implement a well-validated protocol
from the start. Targeted methods may require protocols
specific toward the metabolites of interest. Any reported
metabolomics study should define in detail the sample
collection conditions as part of the method in accordance
with good scientific practice. Peer reviewers and journal
editors can support this practice by requesting this infor-
mation when reviewing submissions.
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